Coagulation Reference Laboratory, Department of Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, the Netherlands.
The Norwegian Organisation for Quality Improvement of Laboratory Examinations, Bergen, Norway.
J Thromb Haemost. 2024 Apr;22(4):1236-1248. doi: 10.1016/j.jtha.2023.12.013. Epub 2023 Dec 20.
Calibration of prothrombin time (PT) in terms of international normalized ratio (INR) has been outlined in "Guidelines for thromboplastins and plasmas used to control oral anticoagulant therapy" (World Health Organization, 2013). The international standard ISO 17511:2020 presents requirements for manufacturers of in vitro diagnostic (IVD) medical devices (MDs) for documenting the calibration hierarchy for a measured quantity in human samples using a specified IVD MD. The objective of this article is to define an unequivocal, metrologically traceable calibration hierarchy for the INR measured in plasma as well as in whole blood samples. Calibration of PT and INR for IVD MDs according to World Health Organization guidelines is similar to that in cases where there is a reference measurement procedure that defines the measurand for value assignment as described in ISO 17511:2020. We conclude that, for PT/INR standardization, the optimal calibration hierarchy includes a primary process to prepare an international reference reagent and measurement procedure that defines the measurand by a value assignment protocol conforming to clause 5.3 of ISO 17511:2020. A panel of freshly prepared human plasma samples from healthy adult individuals and patients on vitamin K antagonists is used as a commutable secondary calibrator as described in ISO 17511:2020. A sustainable metrologically traceable calibration hierarchy for INR should be based on an international protocol for value assignment with a single primary reference thromboplastin and the harmonized manual tilt tube technique for clotting time determination. The primary international reference thromboplastin reagent should be used only for calibration of successive batches of the secondary reference thromboplastin reagent.
根据“世界卫生组织(WHO)关于使用血栓弹力图和血浆控制口服抗凝剂治疗的指南”(2013 年),已经概述了凝血酶原时间(PT)的国际标准化比值(INR)校准。国际标准 ISO 17511:2020 为体外诊断(IVD)医疗器械(MD)制造商规定了要求,用于记录使用特定 IVD MD 在人样本中测量量的校准层次结构。本文的目的是为在血浆和全血样本中测量的 INR 定义一个明确的、计量可追溯的校准层次结构。根据世界卫生组织指南对 IVD MD 的 PT 和 INR 进行校准与在存在定义赋值测量值的参考测量程序的情况下类似,如 ISO 17511:2020 所述。我们的结论是,对于 PT/INR 标准化,最佳的校准层次结构包括一个主要过程,用于制备国际参考试剂和测量程序,该程序通过符合 ISO 17511:2020 第 5.3 条的赋值协议来定义测量值。我们使用新鲜制备的来自健康成年个体和维生素 K 拮抗剂患者的人血浆样本作为可互换的二级校准物,如 ISO 17511:2020 所述。基于具有单一主要参考凝血活酶和协调的手动倾斜管技术用于凝血时间测定的赋值国际协议,应建立 INR 的可持续计量可追溯校准层次结构。主要的国际参考凝血活酶试剂应仅用于校准后续批次的二级参考凝血活酶试剂。